TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03600142

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mashia
Description: Maisha is a brief, scalable, theory-based counseling intervention that addresses HIV stigma at entry into antenatal care. The intervention will be developed in a formative phase and includes 1) a video and counseling session prior to HIV testing that addresses HIV stigma, and 2) two post-test HIV counseling sessions for HIV-infected individuals, building on the video content to provide emotional support, address stigma, and reinforce the value of care engagement.
Study: NCT02821611

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation Group
Description: twice daily 20 minute mantra-based meditation practice for 8 weeks
Study: NCT06243042

Intervention type: DIAGNOSTIC_TEST
Intervention: serum vitamin D
Description: blood sample for serum vitamin D level Vitamin D serum level was measures using the ELISA technique. The Cal Biotech Vitamin D Kit (Mannheim, Germany) was used, which is a solid phase enzyme linked immunoassay (ELISA), based on the principal of competitive binding. Vitamin D deficiency was defined as serum Vit. D below 20 ng/ml.

Intervention type: DIAGNOSTIC_TEST
Intervention: serum vitamin D
Description: blood sample for serum vitamin D level Vitamin D serum level was measures using the ELISA technique. The Cal Biotech Vitamin D Kit (Mannheim, Germany) was used, which is a solid phase enzyme linked immunoassay (ELISA), based on the principal of competitive binding. Vitamin D deficiency was defined as serum Vit. D below 20 ng/ml.

Intervention type: DIAGNOSTIC_TEST
Intervention: urine osmolality
Description: nocturnal urine osmolality: Clear instructions for mothers were to let the child void before sleep and every two hours till 8 am. Short intervals were meant to avoid enuretic episodes during calculation of nocturnal urine volume, and if occurred it mandates the repeat of chart on another day.~Nocturnal urine collected over the night was tested for osmolality, it was measured in mOsm/kg.

Intervention type: DIAGNOSTIC_TEST
Intervention: urine osmolality
Description: nocturnal urine osmolality: Clear instructions for mothers were to let the child void before sleep and every two hours till 8 am. Short intervals were meant to avoid enuretic episodes during calculation of nocturnal urine volume, and if occurred it mandates the repeat of chart on another day.~Nocturnal urine collected over the night was tested for osmolality, it was measured in mOsm/kg.

Intervention type: OTHER
Intervention: Frequency volume chart
Description: volume and frequency from time of sleep till 8 am

Intervention type: OTHER
Intervention: Frequency volume chart
Description: volume and frequency from time of sleep till 8 am
Study: NCT00299962

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adenoviral-mediated Interferon-beta
Description: BG00001 at doses 1.5 x 10e12 and 3 x 10e12 viral particles Days 1 and 8

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adenoviral-mediated Interferon-beta
Description: BG00001 at doses 1.5 x 10e12 and 3 x 10e12 viral particles Days 1 and 8

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCH 721015
Description: Comparison of different doses and frequency of investigational agent

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCH 721015
Description: Comparison of different doses and frequency of investigational agent

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCH 721015
Description: Comparison of different doses and frequency of investigational agent

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCH 721015
Description: Comparison of different doses and frequency of investigational agent

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCH 721015
Description: Comparison of different doses and frequency of investigational agent
Study: NCT03359291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Single oral dose of 10 mg rosuvastatin (film-coated tablet) on Day 1 and Day 10

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macitentan
Description: Single oral dose of 30 mg macitentan (film-coated tablet) on Day 5 and 10 mg macitentan administered orally from Day 6 to Day 16
Study: NCT02365220

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No expectancy (control)
Description: No expectancy instruction with regard to the efficacy of the daily smartphone-based training (exposition to either mock sound or color)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prospective expectancy
Description: Prospective expectancy instruction (Training will have an effect on...) with regard to the efficacy of the daily smartphone-based training (exposition to either mock sound or color)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Retrospective expectancy
Description: Retrospective expectancy instruction (Training already had an effect on...) with regard to the efficacy of the daily smartphone-based training (exposition to either mock sound or color)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prospective and retrospective expectancy
Description: Prospective (Training will have an effect on...) and retrospective (Training already had an effect on...) expectancy instruction with regard to the efficacy of the daily smartphone-based training (exposition to either mock sound or color)
Study: NCT03992664

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EDUCATION
Description: The training program will focus on four parameters: cleanliness, hydration, protection from external stimuli, and finally early detection of skin side effects.~The re-evaluation of the skin as well as the repetition of the questionnaires will be done every week for 4 weeks.
Study: NCT00654914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levitra (Vardenafil, BAY38-9456)
Description: 10 mg per dose of vardenafil for the first four weeks. A further 8 weeks ( in two treatment periods of four weeks, respectively) where patients will either maintain the previous dosage regimen or will step up to 20 mg per dose of vardenafil or will step down to 5 mg per dose of vardenafil, at interval visits of four weeks .
Study: NCT04298736

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bariatric Surgery
Description: laparoscopic Roux-en-Y gastric bypass or laparoscopic Sleeve Gastrectomy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle modification
Description: guided low-calorie diet and physical activity.
Study: NCT01329250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Patients will start on a standard dose of MFX 400 mg once daily. After 8 days the dose will be increased to 600 mg once daily and on the 15th day of treatment, the dose of MFX will be escalated to 800 mg. In patients who have been treated with rifampicin (RIF) in the past three weeks prior to start of MFX treatment an additional washout period of 3 weeks to reduce the rifampicin induced enzymatic activity will precede the dose escalation.
Study: NCT03349775

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: One capsule by mouth twice a day, followed by an increase to two capsules by mouth twice a day for a total of 3 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One capsule by mouth twice a day, followed by an increase to two capsules by mouth twice a day for a total of 3 months
Study: NCT04026698

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resident and Family Engagement Intervention
Description: The leadership coaching component targets managers, administrators/ directors of care in long-term care settings. These sessions involve selecting a subset of relevant performance outcomes from the quality improvement plan that align with leadership vision and priorities for staff performance which leaders can monitor, reinforce and encourage.~The education component involves a one-day in-person training session for staff and managers on communication strategies and ways to engage family and residents in care planning, and includes follow-up visits.~The huddle component involves a series of resident and family led huddles (brief, 15 minute meetings) to discuss a care related topic with staff to foster proactive communication and information sharing. Resident-family dyads will participate in the huddles, along with the staff and management team who received the training. The huddles will be scheduled for 15 minutes once/month for up to 3 months.
Study: NCT00337909

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computerized Plasticity-Based Adaptive Cognitive Training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational DVDs
Study: NCT02718781

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health talk
Description: Health talk on zero-time exercise.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health talk
Description: Health talk on zero-time exercise.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health talk
Description: Health talk on zero-time exercise.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Regular contact with community leaders
Description: Regular contact with community leaders to remind them do zero-time exercise.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Regular contact with community leaders
Description: Regular contact with community leaders to remind them do zero-time exercise.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Handgrip
Description: This is a home-based equipment
Study: NCT01973374

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Message Intervention
Study: NCT02853448

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Novel Blood Drawing Apparatus
Study: NCT04458662

Intervention type: PROCEDURE
Intervention: Interval running protocol / eccentric-based resistance exercise protocol

Intervention type: PROCEDURE
Intervention: Interval running protocol / eccentric-based resistance exercise protocol

Intervention type: PROCEDURE
Intervention: Interval running protocol / eccentric-based resistance exercise protocol
Study: NCT02753322

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dual task training
Description: Balance and walking exercises with simultaneously engaging in attention demanding tasks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Single-task training
Description: Balance and walking exercises and and attention demanding task performed separately

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Limbs exercise
Description: Stretching and strengthening exercises
Study: NCT00434421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycerinated German cockroach allergenic extract
Description: Initially each subject underwent a 1-day, 8-dose escalation (e.g., one dose of placebo, 0.14 milliliters \[mL\], followed by 7 escalating doses of Glycerinated German Cockroach Allergenic Extract until the Maximum Study Dose \[0.42 mL, 1:10 wt/vol\] or Maximum Tolerated Dose was achieved). This maximum dose became the daily dose - maintenance dose- of Glycerinated German Cockroach Allergenic Extract for the following 14 days.The maintenance dose of 0.42 mL was calculated to contain 3685 bioequivalent allergy units (BAU), with approximately 4.2 mg of German cockroach allergen Bla g 2 and 50 mg of Bla g 1 per dose. Route of administration: sublingual-oral route.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo was administered only as the first dose (e.g., representing no Glycerinated German Cockroach bioequivalent allergy units) during the initial 1-day, 8-dose escalation, otherwise referred to as the Preliminary Dosing Visit. Refer to the Glycerinated German cockroach allergenic extract treatment for more details. Route of administration: sublingual-oral route.
Study: NCT00829075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: r-FSH

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HP-hMG

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: r-FSH plus HP-hMG
Study: NCT02877693

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Thoracic MRI Scan
Description: The ICD system will be exposed to MRI scan of thoracic region, where the radiofrequency (RF) component of the scan is maximized.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Thoracic MRI Scan
Description: The ICD system will be exposed to MRI scan of thoracic region, where the radiofrequency (RF) component of the scan is maximized.
Study: NCT01414881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mipomersen
Description: mipomersen 200mg subcutaneously (SC) once weekly

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered subcutaneously (SC) once weekly
Study: NCT02925702

Intervention type: DRUG
Intervention: Radium 223 55mBq/Kg every 4 weeks intravenously
Description: Radium-223 55kBq/kg infusion IV every 4 weeks
Study: NCT01274715

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Health Coaching
Description: Behavioral health coaching consisting of goal-setting, action planning, behavioral activation, and cognitive therapy is delivered by telephone over approximately 3 months.
Study: NCT03075813

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention Cluster
Description: Surgical surveillance date will be analyzed by optimized SPC methods. if signal is generated, study personnel in DICON will be notified to adjudicate the signal and determine if further action is needed.
Study: NCT02495844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UCB0942
Description: Active substance: UCB0942 Pharmaceutical form: Film-coated tablet Concentration: 200 mg Route of Administration: Oral use

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: UCB0942
Description: Active substance: UCB0942 Pharmaceutical form: Film-coated tablet Concentration: 100 mg Route of Administration: Oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UCB0942
Description: Active substance: UCB0942 Pharmaceutical form: Film-coated tablet Concentration: 100 mg Route of Administration: Oral use

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: Film-coated tablet Route of administration: Oral use
Study: NCT02921191

Intervention type: DRUG
Intervention: filgrastim, TBO-filgrastim or pegfilgrastim
Description: First cycle

Intervention type: DRUG
Intervention: filgrastim, TBO-filgrastim or pegfilgrastim
Description: First cycle
Study: NCT02097524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarilumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarilumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tocilizumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tocilizumab
Study: NCT00820911

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclosporine (reduced exposure) / everolimus
Description: twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AEB071 300 mg b.i.d. / everolimus
Description: twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AEB071 200 mg b.i.d. / everolimus
Description: twice daily
Study: NCT02091778

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fast gelling dressing
Study: NCT01025960

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard Inspection Colonoscopy
Description: The large bowel will be inspected for polyps during the withdrawal of the colonoscope to the cecum, and during the withdrawal of the scope from the large bowel.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dual Inspection Colonoscopy
Description: The large bowel will be inspected for polyps during the insertion of the colonoscope to the cecum, and during the withdrawal of the scope from the large bowel.
Study: NCT04638972

Intervention type: DEVICE
Intervention: working length determination techniques
Description: A total of 30 infected mandibular primary second molar teeth in twelve children aged between 5 and 8 years were included in this study. Working length determination was performed using tactile sense, radiographic method and two different varieties of electronic apex locators (ProPex Pixi® and Ipex®) separately.

Intervention type: DEVICE
Intervention: working length determination techniques
Description: A total of 30 infected mandibular primary second molar teeth in twelve children aged between 5 and 8 years were included in this study. Working length determination was performed using tactile sense, radiographic method and two different varieties of electronic apex locators (ProPex Pixi® and Ipex®) separately.

Intervention type: DEVICE
Intervention: working length determination techniques
Description: A total of 30 infected mandibular primary second molar teeth in twelve children aged between 5 and 8 years were included in this study. Working length determination was performed using tactile sense, radiographic method and two different varieties of electronic apex locators (ProPex Pixi® and Ipex®) separately.

Intervention type: DEVICE
Intervention: working length determination techniques
Description: A total of 30 infected mandibular primary second molar teeth in twelve children aged between 5 and 8 years were included in this study. Working length determination was performed using tactile sense, radiographic method and two different varieties of electronic apex locators (ProPex Pixi® and Ipex®) separately.
Study: NCT01417598

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gait and balance group training
Description: The balance-training program is based on scientifically well-established principles of exercise training and postural control as well as current research on training in elderly and PD. For the PD group it has been modified based on the current knowledge of the neurophysiology and the inevitable constraints on mobility and postural control resulting from basal ganglia degeneration. The training will be conducted as a progressive individually adjusted group program, led by experienced physiotherapists and researchers in order to challenge the specific balance disorder of every participant and endorse progression. It is progressive and specific balance program including dual- and multitasks. The program is performed 3 times/week for 10-12 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nordic walking (only osteoporosis group)
Description: To further test the hypothesis that physical activity may enhance the results from the balance training program pole striding will be added to the balance training program, at least 30-45 minutes three times per week during leisure time. Each individual in this group will be provided with individually adjusted poles, a pedometer and a diary to enter when and for how long time they have been walking.
Study: NCT04311697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aviptadil by intravenous infusion + standard of care
Description: Aviptadil by intravenous infusion + standard of care (SOC). SOC is defined not to include extracorporeal mechanical oxygenation. Those requiring ECMO will be withdrawn from the study as treatment failures.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal Saline Infusion + standard of care
Description: Saline by intravenous infusion + standard of care (SOC). SOC is defined not to include extracorporeal mechanical oxygenation. Those requiring ECMO will be withdrawn from the study as treatment failures.
Study: NCT02285920

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Spironolactone
Description: The trial will be conducted in 2 phases - a dose escalation phase (6 weeks) and a treatment phase (30 weeks). At the end of the dose escalation phase, participants will continue treatment based on the randomized dose assignment for an additional 30 weeks (treatment phase) such that the total duration of study medication is 36 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spironolactone
Description: The trial will be conducted in 2 phases - a dose escalation phase (6 weeks) and a treatment phase (30 weeks). At the end of the dose escalation phase, participants will continue treatment based on the randomized dose assignment for an additional 30 weeks (treatment phase) such that the total duration of study medication is 36 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spironolactone
Description: The trial will be conducted in 2 phases - a dose escalation phase (6 weeks) and a treatment phase (30 weeks). At the end of the dose escalation phase, participants will continue treatment based on the randomized dose assignment for an additional 30 weeks (treatment phase) such that the total duration of study medication is 36 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spironolactone
Description: The trial will be conducted in 2 phases - a dose escalation phase (6 weeks) and a treatment phase (30 weeks). At the end of the dose escalation phase, participants will continue treatment based on the randomized dose assignment for an additional 30 weeks (treatment phase) such that the total duration of study medication is 36 weeks.
Study: NCT04594382

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Pupillometry-Opioid treatment
Description: At the end of anesthesia, before extubation, pupillometry measurements will be performed on both eyes, using the tetanus mode T30 (30mA tetanic stimulation) and T60 (60mA tetanic stimulation) and the standardized pupillary pain index (PPI) mode at the pupillometer.~Opioid administration will be given by a single dose of piritramid (0.1 mg kg -1) in case of measured PDR values of ≥12 (high analgesic sensitivity as specified by the producer) after T30 and T60 stimulation. The pupillometry measurement will be repeated once on both eyes.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Pupillometry -standardized opioid treatment
Description: At the end of anesthesia, before extubation, pupillometry measurements will be performed on both eyes, using the tetanus mode T30 (30mA tetanic stimulation) and T60 (60mA tetanic stimulation) and the standardized pupillary pain index (PPI) mode at the pupillometer.~A standardized single dose of piritramid (0,1 mg kg -1) will be given intravenously, regardless of the measured values. The pupillometry measurement will be repeated once on both eyes.
Study: NCT03420014

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: 75 mg/m2 doxorubicin will be administered once every 3 weeks (Day 1 of every 21-days cycle).

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: L19TNF plus doxorubicin
Description: 13 μg/kg L19TNF will be administered on day 1, 3 and 5 of every 21-days cycle in combination with 60 mg/m2 doxorubicin on day 1 of every 21-days cycle.
Study: NCT01871220

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Concave Transition Profile
Description: An Atlantis abutment is delivered with a concave transition profile.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Divergent Transition Profile
Description: An Atlantis abutment is delivered with a linear transition profile